Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Machado ‘presented’ her Nobel Peace Prize medal to Trump - 2Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- 3A Manual for Nations with Extraordinary Food
- 4James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- 5German police 'cleared path for fascists with batons,' protesters say
- The race to mine the moon is on – and it urgently needs some clear international rules
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- ‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Central African Republic's president sworn in for a third term after disputed election
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Nature's Treats: 10 Organic products That Lift Prosperity
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
